Neoadjuvant Immunotherapy for Hepatocellular Carcinoma

The treatment paradigm for hepatocellular carcinoma (HCC) had been stagnant until recently, with new combinations of targeted and immunotherapies entering the first- and second-line setting for patients with advanced disease. This improvement in therapeutic options is well timed given the rise in ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Marron, Thomas U, Schwartz, Myron, Corbett, Virginia, Merad, Miriam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252295/
https://www.ncbi.nlm.nih.gov/pubmed/35794901
http://dx.doi.org/10.2147/JHC.S340935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252295/
https://www.ncbi.nlm.nih.gov/pubmed/35794901
http://dx.doi.org/10.2147/JHC.S340935

Ejemplares similares